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Abstract
Canine cognitive dysfunction (CCD) is an age-dependent neurodegenerative condition characterised by changes in decline in learning and memory patterns.
The neurodegenerative features of CCD in ageing dogs and cats are similar to human ageing and Alzheimer’s disease (AD). Discovering neuroprotective
disease-modifying therapies against CCD and AD is a major challenge. Strong evidence supports the role of amyloid β peptide deposition and oxidative
stress in the pathophysiology of CCD and AD. In both the human and canine brain, oxidative damage progressively increases with age. Dietary antioxidants
from natural sources hold a great promise in halting the progression of CCD and AD. Withania somnifera (WS), an Ayurvedic tonic medicine, also known as
‘Indian ginseng’ or ashwagandha has a long history of use in memory-enhancing therapy but there is a dearth of studies on its neuroprotective effects. The
objective of this study was to investigate whetherWS extract can protect against Aβ peptide- and acrolein-induced toxicity. We demonstrated that treatment
with WS extract significantly protected the human neuroblastoma cell line SK-N-SH against Aβ peptide and acrolein in various cell survival assays.
Furthermore, treatment with WS extract significantly reduced the generation of reactive oxygen species in SK-N-SH cells. Finally, our results showed
that WS extract is also a potent inhibitor of acetylcholinesterase activity. Thus, our initial findings indicate that WS extract may act as an antioxidant
and cholinergic modulator and may have beneficial effects in CCD and AD therapy.
Key words: Withania somnifera: Amyloid β-peptide: Acrolein: Oxidative stress: Acetylcholinesterase
Canine cognitive dysfunction (CCD) and Alzheimer’s disease
(AD) are the most common age-related neurodegenerative dis-
orders affecting millions of pets and people worldwide. It is
now well established that both oxidative stress and Aβ peptide
have been implicated in the pathogenesis of CCD and AD(1).
Aβ peptide is formed and released after the sequential cleavage
of the amyloid precursor protein by β- and γ-secretases,
respectively. Aβ peptide, a 40–42 amino acid-long peptide,
is an important component of senile plaque formation in
AD brain(2) and its toxicity is mediated through the generation
of hydrogen peroxide (H2O2)
(3,4). Reactive oxygen species
(ROS), on the other hand, generate highly electrophilic
α,β-unsaturated carbonyl derivatives including acrolein,
4-hydroxy-2-nonenal, and 4-oxononenal from the peroxidation
of membrane lipids(5). In AD brain, levels of acrolein were
found to be significantly higher in several brain regions such
as in the hippocampus, amygdala, middle temporal gyrus and
cerebellum(6,7). In primary neuronal cultures from the hippo-
campus, the toxicity of acrolein was higher than 4-hydroxy-2-
nonenal(8). We have recently established on a neuronal cell
line SK-N-SH the details of the multiprocess step of the toxicity
of acrolein(9). We showed that, in addition to being a byproduct
of lipid peroxidation, acrolein could also potentiate oxidative
damage and activate several redox-sensitive pathways.
Abbreviations: AChE, acetylcholinesterase; AD, Alzheimer’s disease; CCD, canine cognitive dysfunction; DCF-DA, 2′,7′-dichlorofluorescein diacetate; DMEM, Dulbecco’s
minimum essential medium; DTNB, 5,5′-dithiobis-2-nitrobenzoic acid; LDH, lactate dehydrogenase; ROS, reactive oxygen species; WS, Withania somnifera.
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Incidence rates of age-specific AD in rural India are at least
three times lower than those of an age-matched American ref-
erence population(10), which could be attributed to genetic,
environmental or dietary causes. Withania somnifera (WS) is
one of the most important medicinal plants used in the
Indian system of traditional medicine as a nootropic agent
and brain tonic to restore age-related decline in mental abil-
ities(11). The major biochemical constituents ofWS are steroidal
alkaloids and steroidal lactones saponins, together called witha-
nolides(12). Presently more than twelve alkaloids and forty with-
anolides have been identified and characterised from the leaves,
roots and berries of Withania species which either exist in free
form, i.e. withanone, withaferin A, withanolide A, withanolides
D-M, withanolides I–III, or in glycosidic form, i.e. withanosides
I–VI(13). RecentlyWS extract has been shown to protect against
Aβ peptide- and H2O2-induced toxicities
(14–16). In spite of its
widespread use as a brain tonic, its neuroprotective activity
against acrolein remains poorly investigated.
Since multi-factorial causes have been recognised in CCD
and AD as well as in other neurodegenerative disorders,
CCD and AD will require multiple drug therapy to address
the varied pathological aspects. Even if the strategy of combin-
ing drugs with different therapeutic targets is workable, the
new pharmacological approach is to develop a multi-functional
compound or extract to target multiple sites in the brain.
Thus, the purpose of the present investigation was to demon-
strate if a treatment with a standardised extract of WS can
protect the human neuroblastoma cell line SK-N-SH against
Aβ peptide- and acrolein-induced toxicity, decrease ROS levels
and inhibit acetylcholinesterase (AChE) activity.
Materials and methods
Drugs and chemicals
A standardised extract of WS was kindly provided by Natural
Remedies Private Limited, Bangalore, India. WS extract was
certified to contain 2·6 % withanolides including withanosides
IV (0·87 %) and V (0·65 %), withaferin A (0·56 %), withano-
lide A (0·20 %) and B (0·06 %), and 12-deoxy withastramono-
lide (0·26 %) as determined by HPLC. Dulbecco’s minimum
essential medium (DMEM), fetal bovine serum, penicillin/
streptomycin, acrolein, acetylthiocholine iodide, neostigmine
bromide, 5,5′-dithiobis-2-nitrobenzoic acid (DTNB), H2O2
and TOX-2 (XTT based) were obtained from Sigma-Aldrich
Inc. The cytotoxicity detection kit based on the lactate
dehydrogenase (LDH) assay was from Roche Diagnostics
and 2′,7′-dichlorofluorescein diacetate (DCF-DA) was from
Invitrogen. β-Amyloid peptide(25–35) was purchased from
American Peptide.
Aβ25–35 preparation
The synthetic peptide Aβ25–35 was dissolved in sterilised tap
water and incubated at 37°C for 72 h for fibrillisation before
use as previously described(17). Although both soluble and
fibrillar Aβ peptide can induce oxidative stress, the latter is
more efficient in causing lipid peroxidation(18).
Cell culture and treatment
For neuroprotective effects of WS, SK-N-SH cells, a human
neuroblastoma cell line from American Type Cell Culture
(ATCC), were maintained in DMEM supplemented with
10 % (v/v) fetal bovine serum, 100 U/ml penicillin and
100 µg/ml streptomycin. SK-N-SH cells were plated at a dens-
ity of 1·5 × 104 cells/well in ninety-six-well-plates (Corning)
and incubated at 37°C. After 24 h of plating, the medium
was completely removed and cells were kept in DMEM with
antibiotics but without serum. Cells were then treated with
toxic doses of Aβ (50 µg/ml) for 48 h or with acrolein
(20 µM) for 24 h.
Cell viability assays
Cytotoxicity and cell survival were measured by LDH and
XTT assays by using commercial kits as previously
described(19). The XTT assay measures mitochondrial dehy-
drogenases activity and may reflect the cellular metabolic
state and serves as an indicator of cell survival. Because of
the proliferative effects of the WS extract, cells may have
higher dehydrogenases activity and the XTT test alone
would not be sufficient to measure the neuroprotective effects.
To further confirm the protective effects of theWS extract, we
employed the LDH test; which measures cellular membrane
integrity and is a mean of quantifying dead cells.
Intracellular reactive oxygen species level
The antioxidant activity ofWS was confirmed by measuring its
ability to scavenge ROS in SK-N-SH cells by using the fluor-
escent dye DCF-DA as previously described(19). DCF-DA, a
cell0permeable dye, is enzymically converted to a strongly
fluorescent compound DCF in the presence of cellular ROS
and the fluorescent intensity is directly proportional to the
intracellular ROS level.
Acetylcholinesterase inhibition
The relative AChE- inhibitory activity ofWS extract was deter-
mined in rat brain homogenates by a spectrophotometric
method(20,21). The reaction mixture containing 50 µl of
DTNB (3 mM), 25 µl WS extract, 25 µl brain homogenate
from a pool of several Sprague–Dawley rats (100 µg total pro-
tein) and 100 µl of phosphate buffer. The reaction was started
with the addition of 50 µl acetylthiocholine iodide (15 mM).
Enzymic hydrolysis of acetylthiocholine iodide releases thio-
choline, which forms a yellow 5-thio-2-nitrobenzoate anion
as a result of the reaction with DTNB. The plate was read
kinetically at λ 412 nm for 300 s and change in optical dens-
ity/min was calculated. Neostigmine bromide (6·25 nM) was
taken as a positive control.
Data analysis
All results were confirmed in four or five separate independent
experiments with at least three technical replicates each time
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and expressed as means with their standard errors. The
GraphPad InStat3 program (GraphPad Software) was used
for data analysis. Statistical analysis was done by one-way
ANOVA followed by Dunnett’s multiple means comparison
test and significance was considered when P was <0·05.
Results
Withania somnifera extract protects SK-N-SH cells against Aβ
peptide- and acrolein-induced toxicity
Results in Tables 1 and 2 show that treatment with the WS
extract protects SK-N-SH cells against Aβ peptide- and
acrolein-induced toxicity. This protection was assessed 48 h
after the addition of Aβ peptide and was significant from
1·0 and 5·0 µg/ml for the LDH and XTT assays, respectively
(Table 1). Interestingly, treatment with the WS extract could
also protect SK-N-SH cells against toxicity induced by acrolein
from 12·5 µg/ml of WS and reached a maximum at 25 µg/ml
(Table 2). To rule out any false-positive effects and interfer-
ence with the XTT and LDH assays, absorbance was read
and no interference was observed with the different doses of
WS tested.
Withania somnifera extract decreases intracellular reactive
oxygen species level
Since ROS and oxidative damages are involved in the toxicity
of Aβ peptide and acrolein, we investigated the antioxidant
activity of WS. The WS extract was able to decrease the levels
of ROS in SK-N-SH cells treated with H2O2 (500 µM), with a
significant effect observed from 5·0 µg/ml (Supplementary
Fig. S1).
Withania somnifera extract has potent
acetylcholinesterase-inhibitory activity
The so-called cholinergic hypothesis of AD proposed that
degeneration of cholinergic neurons in the basal forebrain
and the associated loss of cholinergic neurotransmission in
the cerebral cortex and other areas contribute significantly to
the deterioration in cognitive function seen in patients with
AD(22). AChE is the key component of cholinergic synaptic
transmission and plays a major role in the termination of
impulse transmission by rapid hydrolysis of the neurotransmit-
ter acetylcholine. This serves as a rationale for the use of three
Food and Drug Administration-approved AChE inhibitors in
the symptomatic treatment of AD(23). We thus investigated the
effect of WS on the activity of AChE on brain homogenates.
As shown in Fig. 1, AChE activity was reduced by 30 % using
12·50 µg/ml of WS and reached about 50 % of inhibition at
50 µg/ml of WS.
Discussion
There is growing interest in naturally derived bioactive com-
pounds for pharmacological application for the treatment of
CCD and AD. Different strategies are being investigated such
as the neuroprotective therapeutic approach based on protection
against Aβ-induced neurotoxicity and oxidative damage or
inhibition of AChE. In the present study, our results showed
that the WS extract could significantly protect SK-N-SH cells
against Aβ- and acrolein-induced toxicity, decrease ROS levels
in SK-N-SH cells and inhibit the activity of AChE. The protect-
ive effect against Aβ is consistent with other studies that have
suggested thatWSmay be neuroprotective by mediating antioxi-
dant effects. Similar to curcuminoids and ginkgolides,
Table 1. Effect of treatment with Withania somnifera (WS) on SK-N-SH cell survival after 24 h with Aβ peptide (50 µg/ml) using lactate dehydrogenase
(LDH) and XTT assays†
(Mean values with their standard errors of four or five separate experiments performed in triplicate at least in each group)
Aβ (50 µg/ml) +WS (μg/ml)
Control Aβ (50 μg/ml) WS-0·5 WS-1·0 WS-5·0
Assay Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
LDH 100·0** 3·61 134·32 6·32 122·11 4·10 114·25** 3·79 109·28** 2·80
XTT 100·0** 4·98 42·31 6·08 62·17 7·32 69·03 13·75 71·87* 4·03
Mean value was significantly different from that of the Aβ group: * P < 0·05, ** P < 0·01.
† Results are expressed as percentage of control (taken as 100 %).
Table 2. Effect of treatment with Withania somnifera (WS) on SK-N-SH cell survival after 24 h with acrolein (20·0 µM) using lactate dehydrogenase (LDH)
and XTT assays†
(Mean values with their standard errors of four or five separate experiments performed in triplicate at least in each group)
Acrolein (20 µM) +WS (μg/ml)
Control Acrolein (20 µM) WS-12·5 WS-25·0
Assay Mean SEM Mean SEM Mean SEM Mean SEM
LDH 100·0** 4·42 215·24 7·37 139·73** 9·90 127·21** 5·96
XTT 100·0** 2·23 48·92 9·95 80·78** 6·37 81·67** 1·05
** Mean value was significantly different from that of the acrolein group (P < 0·01).
† Results are expressed as percentage of control (taken as 100 %).
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withanamides fromWS fruit showed potent antioxidant activity
as indicated by their ability to inhibit lipid oxidation(24). In our
study, the neuroprotective effect against Aβ could not be attrib-
uted to the effects of WS on ROS scavenging as its effect on
ROS levels was significant from 5 µg/ml while cytoprotection
was observed at lower concentrations (1 µg/ml). Other mechan-
isms should be investigated such as the effects ofWS on redox-
sensitive pathways because it has been demonstrated that with-
aferin A, the major constituents of the extract, could inhibit
the activity of the transcription factors NF-κB, or AP-1(25).
Also, the WS extract was more effective than withanamide A,
one of the major components of WS, against Aβ because with-
anamide A was inactive until 12·5 µg/ml(15). These results indi-
cate that other components from the WS extract are implicated
in the neuroprotective effect against Aβ such as sominone, the
active metabolite of withanoside IV(14).
The present study demonstrated the protective effect of WS
against acrolein. This result is of great interest as acrolein has
been shown to be elevated in the brain from AD, from mild
cognitive impairment and from preclinical AD(26) and could
induce neuronal and glial toxicity(9). Different mechanisms
could underlie this protection such as the antioxidant activity
of WS because acrolein has been shown to increase the pro-
duction of superoxide, activate NADPH oxidase activity and
deplete reduced glutathione levels(27). Moreover, among the
α,β-unsaturated aldehydes, acrolein reacts 110–150 times fas-
ter with glutathione than 4-hydroxy-2-nonenal or crotonal(9).
The effects of WS on the activity of redox-sensitive pathways
could also be involved as we have recently shown that the tox-
icity of acrolein modulates different signalling pathways(9).
The inhibition of AChE activity by WS from 12·5 µg/ml
described here is in line with the effects of withanolides on
AChE with an half maximal inhibitory concentration (IC50)
ranging between 20·5 and 49·2 µg/ml(28).
WS components have been shown to induce outgrowth of
axons and dendrites, and memory enhancement. Tohda &
Joyashiki(29) have demonstrated that sominone, an active
metabolite of withanoside IV, could induce the phosphorylation
of RET (rearranged during transfection), a receptor for glial cell
line induced neurotropic factor (GDNF). Pharmacokinetics
studies in mice suggested rapid oral absorption of withanolides
and revealed that withaferin A has one and half times more rela-
tive bioavailability as compared with withanolide A(30). Recent
studies have shown that WS extract reversed brain pathology
inmousemodels of Alzheimer’s and amyotropic lateral sclerosis,
thereby indicating that certain components are bioavailable and
cross the blood brain–barrier(31,32).
Thus, cholinesterase-inhibiting potential along with antioxi-
dant ability and neurotrophic and neuroprotective activity
against Aβ peptide and acrolein could make WS extract and
its constituents possible therapeutic agents in CCD, AD and
senile dementia. Our investigation further strengthens the trad-
itional use of WS as a nootropic agent for restoring age-related
decline in mental abilities. However, further exploratory animal
studies are needed to optimise therapeutic doses, to find out
the right therapeutic compounds that can cross the blood–
brain barrier and the duration of WS treatments aiming to
yield desired beneficial outcomes; this further represents chal-
lenges as some of the components such as withaferin A are
potentially cytotoxic(33).
Supplementary material
The supplementary material for this article can be found at
https://doi.org/10.1017/jns.2017.48
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